ADEF
FPRX

Adams Diversified Equity Fund’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Adams Diversified Equity Fund’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-18,600
Closed -$672K – 224
2017
Q1 		$672K Buy
18,600
+6,700
+56% +$295K 0.04% 202
2016
Q4 		$596K Buy
+11,900
New +$625K 0.04% 206

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adams Diversified Equity Fund's FPRX Position: Q2 2017 in Review

Adams Diversified Equity Fund sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 18,600 shares — an estimated $672K sold.

Adams Diversified Equity Fund first reported a position in FPRX in Q4 2016 and held it in 2 quarters. The position peaked at $672K in Q1 2017. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • Adams Diversified Equity Fund reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Adams Diversified Equity Fund sold 18,600 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $672K.
  • Adams Diversified Equity Fund first reported a position in Five Prime Therapeutics, Inc. in Q4 2016 and held it in 2 quarters.
  • Adams Diversified Equity Fund's Five Prime Therapeutics, Inc. position peaked at $672K in Q1 2017.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Adams Diversified Equity Fund's 13F filing for Q2 2017, filed 21 Jul 2017.